Bologna, 13 March 2009 - The Board of Directors of NoemaLife today approved the consolidated balance sheet at 31 December 2008 and the Balance sheet of the parent company on the same date.
The consolidated operating revenues were equal to 34.4 million Euros, up 53% compared with 22.5 million the previous year.
Consolidated EBITDA stood at 6.8 million Euro (20% of operating revenues), increasing compared with 2007 (+41%).
The Net Income for the Group amounted to 1,4 million Euros, as the 1,4 million Euro in 2007.
The net financial position at 31/12/2008 was negative for Euro 16,342 thousand compared to a negative value of Euro 7491 at 31/12/2007.
The Parent Company NoemaLife Spa closed the balance sheet at 31 December 2008 with total operating revenues at 30.8 million Euros, increasing 44% (21.4 million Euro in 2007) and a net profit of 2,3 million Euros, a considerable increase compared with 1 million Euros in 2007 (+120%).
The year 2008 was a year of strong growth for the Group NoemaLife, marked by significant successes on the trade front, and excellent growth in Operating Revenues at 34.4 million euros (+53%), confirming the upward trend in the Group.
On the Italian market, NoemaLife confirms its role as a leading actor. Some significant successes for the year 2008 are:
• The new Hospital Information System Hospital S. Raffaele in Milano. The system computerizes the surgical route, Integration with the SAP system, ITACA for Clinical Data Repository and Analysis Labs;
• The SCREENING Management System in Umbria Region;
• Pathology management systems’ Network for the Calabria region;
• Enablement of the first RIS / PACS at the Policlinico Umberto I, Rome;
• Award of the SILUS tender regarding all the Analys laboratories the Sardinia Region.
Also in the international activities of the Group, the year 2008 has seen major successes, including:
• European Project “ReMINE”, which springs from the widespread need to perform an effective risk prevention for the health of the patient. The Group company based in Berlin (NoemaLife GmbH) is the coordinator of the 15 participating partners, representing 10 countries.
• A new contract was signed with one of the largest institutions of Dermatology in Germany for the supply of Galileo.
• A new Galileo customer was acquired In Chile, Hospital Padre Hurtado in Santiago.
• The hospital of El Cruce (Buenos Aires) has become Galileo's first customer in Argentina.
• In Germany, three new Customers of the Anatomic Pathology Solution have been acquired.
• In September was set up the company NoemaLife CareNet BV in the Netherlands, a joint venture of NoemaLife Gmbh (with a minority of 5%) and Galileo distributor for the Benelux
The success of Group business is confirmed by the substantial increase in order backlog, which stood at 26 million Euros on 31.12.2008 (+40% compared with 31.12.2007) and demonstrates both the effectiveness of Commercial Activities of the Group in the period considered and its ability to generate revenues for the future.
During the financial year some important operations of exceptional nature, greatly enhancing the Group NoemaLife have been carried out:
• The company Ferrania LifeWeb Savona, operating in the area of information systems for clinical radiology was acquired in June.
• 100% of Ferrania UK Ltd in Bracknell working in the area of information systems for radiology clinic in the UK market was also acquired.
• NoemaLife acquired the LIS business unit of Dasit SpA (the software Dasilab Delphi everything linked to it).
• 60% of MTT Pro Srl was acquired, MTT Pro operates in information systems for clinical oncology.
Note that the balance sheet data are under review by the Board of Statutory Auditors and the Independent Reviewers.
The data above will be submitted to the Shareholders Assembly convened for the day April 20 2009.
The Council deliberated the proposal at the shareholders' meeting to carry forward the net profit for the year.
